IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial February 23, 2026 Read More »
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia April 20, 2026 Read More »
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout April 14, 2026 Read More »
